AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q3 2021 vs. Q2 2021
How the institutions holding AIM ImmunoTech Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 39 | 38 | −1 |
| Shares | 7.21M | 7.30M | +94.9K (+1.3%) |
| Value | $15.5M | $14.7M | −$746.0K (−4.8%) |
New holders (6)
Institutions that held AIM ImmunoTech Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Millennium Management LLC | 54,376 | $110.0K | 0.00% |
| Susquehanna International Group, LLP | 36,149 | $73.0K | 0.00% |
| Arkadios Wealth Advisors | 21,597 | $43.0K | 0.01% |
| Alpine Global Management, LLC | 18,774 | $38.0K | 0.01% |
| Qube Research & Technologies Ltd | 15,826 | $32.0K | 0.00% |
| Howe & Rusling Inc | 1,500 | $3.00K | 0.00% |
Sold out (7)
Institutions that held AIM ImmunoTech Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Renaissance Technologies LLC | 152,848 | $329.0K |
| XTX Topco Ltd | 29,269 | $63.0K |
| Charles Schwab Investment Management Inc | 20,316 | $44.0K |
| Lehman & Derafelo Financial Resources LLC | 11,100 | $24.0K |
| Tower Research Capital LLC (TRC) | 9,733 | $21.0K |
| FMR LLC | 1 | $0 |
| Royal Bank of Canada | 14 | $0 |